Table Of Contents:
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Ulcerative Colitis Market: By Product Type
- Product Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Product Type Definitions, Technology Landscape
- Product Type Market Drivers
- Product Launches
- Technology Launches
- Product Type Market Restraints
- Chapter 4. Ulcerative Colitis Market: By Route of Administration
- Route of Administration Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Route of Administration Definitions, Technology Landscape
- Route of Administration Market Drivers
- Product Launches
- Technology Launches
- Route of Administration Market Restraints
- Chapter 5. Ulcerative Colitis Market: By Disease Type
- Disease Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Disease Type Definitions, Technology Landscape
- Disease Type Market Drivers
- Product Launches
- Technology Launches
- Disease Type Market Restraints
- Chapter 6. Ulcerative Colitis Market: By End-User
- End-User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- End-User Definitions, Technology Landscape
- End-User Market Drivers
- Product Launches
- Technology Launches
- End-User Market Restraints
- Chapter 7. Ulcerative Colitis Market: By Distribution Channel
- Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Distribution Channel Definitions, Technology Landscape
- Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- Distribution Channel Market Restraints
- Chapter 8. Ulcerative Colitis Market: North America
- North America Market Size (US$), CAGR (%), and Forecast (2021-2031)
- North America Definitions, Technology Landscape
- North America Market Drivers
- Product Launches
- Technology Launches
- North America Market Restraints
- Competitive Outlook
- Chapter 9. Ulcerative Colitis Market: Europe
- Europe Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Europe Definitions, Technology Landscape
- Europe Market Drivers
- Product Launches
- Technology Launches
- Europe Market Restraints
- Competitive Outlook
- Chapter 10. Ulcerative Colitis Market: Asia Pacific
- Asia Pacific Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Asia Pacific Definitions, Technology Landscape
- Asia Pacific Market Drivers
- Product Launches
- Technology Launches
- Asia Pacific Market Restraints
- Competitive Outlook
- Chapter 11. Ulcerative Colitis Market: Latin America
- Latin America Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Latin America Definitions, Technology Landscape
- Latin America Market Drivers
- Product Launches
- Technology Launches
- Latin America Market Restraints
- Competitive Outlook
- Chapter 12. Ulcerative Colitis Market: Middle East & Africa
- Middle East & Africa Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Middle East & Africa Definitions, Technology Landscape
- Middle East & Africa Market Drivers
- Product Launches
- Technology Launches
- Middle East & Africa Market Restraints
- Competitive Outlook
- Chapter 13. Ulcerative Colitis Market: Competitive Landscape
- AbbVie Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Roche Holding AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Allergan plc (acquired by AbbVie)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck & Co., Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eli Lilly and Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- UCB S.A.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Gilead Sciences, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Amgen Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Celgene Corporation (acquired by Bristol-Myers Squibb)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sanofi
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Ferring Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Shire plc (acquired by Takeda)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Galapagos NV
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AbbVie Inc.
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Ulcerative Colitis industry is US$ 6.7 billion.
The rising prevalence of ulcerative colitis, increasing demand for effective treatments, advancements in drug development, and improving healthcare infrastructure are some of the key factors contributing to the growth of the Ulcerative Colitis market.
High cost of novel therapies, side effects associated with existing treatments, lack of awareness and diagnosis in developing regions, and reimbursement challenges are some of the key factors hampering the growth of the Ulcerative Colitis market.
The leading component segment in the Ulcerative Colitis Market is the Biologics segment, which includes advanced therapeutic options like anti-TNF agents and anti-integrin agents.
The major players operating in the Ulcerative Colitis Market include AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Roche Holding AG, and others.
The Ulcerative Colitis Market is expected to grow at a CAGR of 5.9% and reach a market size of US$ 10.6 billion by 2031.
The key drivers of the Ulcerative Colitis Market include rising prevalence of the disease, increasing demand for effective treatments, advancements in drug development, improving healthcare infrastructure, and growing awareness about the condition.